In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Hims & Hers Health (NYSE:HIMS) over the past three months, with a majority being bullish. The average 12-month price target has increased by 9.75% to $22.17. The company shows strong financial health with significant revenue growth and efficient cost management.
October 21, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hims & Hers Health has received mixed analyst ratings, with a majority being bullish. The average price target has increased by 9.75% to $22.17, indicating positive sentiment. The company shows strong financial health with a 51.82% revenue growth rate.
The majority of analysts are bullish on Hims & Hers Health, with an increased average price target, reflecting positive sentiment. The company's strong financial performance, including significant revenue growth, supports a likely positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100